Side-by-side comparison
Amgen vs Eli Lilly and
As of Sep 25, 2026, P/E is 25.8x for Amgen vs 39.7x for Eli Lilly and; P/S is 5.9x for Amgen vs 14.0x for Eli Lilly and; revenue growth is 9.1% for Amgen vs 49.6% for Eli Lilly and; net margin is 23.0% for Amgen vs 33.5% for Eli Lilly and.
Key metrics
| Metric | AMGN | LLY |
|---|---|---|
| Price | $414.61 | $1,183.46 |
| Market cap | $224.15B | $1.11T |
| P/E | 25.8x (#1) | 39.7x (#2) |
| P/S | 5.9x (#1) | 14.0x (#2) |
| Revenue growth | 9.1% (#2) | 49.6% (#1) |
| Operating margin | 30.0% (#1) | — |
| Net margin | 23.0% (#2) | 33.5% (#1) |
| Debt / equity | 4.44 (#2) | 1.41 (#1) |
| 1-year return | +51.9% (#2) | +63.3% (#1) |
| Research score | 67/100 (#2) | 69/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Amgen Inc. (AMGN) — Drug Manufacturers—General
- Eli Lilly and Company (LLY) — Drug Manufacturers—General